What is a stock summary page? Click here for an overview.
Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Compare
Compare
Traded in other countries / regions
VYGR.USAVT6.GermanyVYGR.Mexico Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2015-11-11Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.1 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | -0.56 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.34 | |||||
| Beneish M-Score | 10.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.8 | |||||
| 3-Year EBITDA Growth Rate | 9.2 | |||||
| 3-Year EPS without NRI Growth Rate | 15.8 | |||||
| 3-Year FCF Growth Rate | 39.3 | |||||
| 3-Year Book Growth Rate | 29.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.14 | |||||
| 9-Day RSI | 28.14 | |||||
| 14-Day RSI | 30.46 | |||||
| 3-1 Month Momentum % | -31.66 | |||||
| 6-1 Month Momentum % | -29.9 | |||||
| 12-1 Month Momentum % | -58.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.56 | |||||
| Quick Ratio | 5.56 | |||||
| Cash Ratio | 5.36 | |||||
| Days Sales Outstanding | 91.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13 | |||||
| Shareholder Yield % | -77.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -104.11 | |||||
| Net Margin % | -81.25 | |||||
| FCF Margin % | -23.54 | |||||
| ROE % | -21.07 | |||||
| ROA % | -15.65 | |||||
| ROIC % | -75.39 | |||||
| 3-Year ROIIC % | -19.87 | |||||
| ROC (Joel Greenblatt) % | -160.81 | |||||
| ROCE % | -23.07 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.22 | |||||
| PB Ratio | 0.57 | |||||
| Price-to-Tangible-Book | 0.57 | |||||
| EV-to-EBIT | 0.42 | |||||
| EV-to-EBITDA | 0.44 | |||||
| EV-to-Forward-EBITDA | -0.03 | |||||
| EV-to-Revenue | -0.43 | |||||
| EV-to-Forward-Revenue | 0.04 | |||||
| EV-to-FCF | 1.84 | |||||
| Price-to-GF-Value | 0.8 | |||||
| Price-to-Projected-FCF | 2.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.93 | |||||
| Price-to-Net-Cash | 0.98 | |||||
| Earnings Yield (Greenblatt) % | 238.1 | |||||
| FCF Yield % | -10.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYGR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80.001 | ||
| EPS (TTM) ($) | -1.13 | ||
| Beta | 1.55 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 51.99 | ||
| 14-Day RSI | 30.46 | ||
| 14-Day ATR ($) | 0.23905 | ||
| 20-Day SMA ($) | 3.8505 | ||
| 12-1 Month Momentum % | -58.83 | ||
| 52-Week Range ($) | 3.1 - 9.72 | ||
| Shares Outstanding (Mil) | 55.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Voyager Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(VYGR)'s stock price today?
The current price of VYGR is $3.11. The 52 week high of VYGR is $9.72 and 52 week low is $3.10.
When is next earnings date of Voyager Therapeutics Inc(VYGR)?
The next earnings date of Voyager Therapeutics Inc(VYGR) is 2025-05-13 Est..
Does Voyager Therapeutics Inc(VYGR) pay dividends? If so, how much?
Voyager Therapeutics Inc(VYGR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers